Лучшие больницы для «Brain Cancer Treatment» в Хайдарабад, Индия

The cost of brain cancer treatment in India typically ranges from $6,000 to $25,000 USD for the primary intervention (craniotomy or stereotactic radiosurgery) including hospital stay, neurosurgical fees, theatre charges, standard medications, and ICU/HDU monitoring. At JCI- and NABH-accredited hospitals in cities such as Chennai, Hyderabad, Mumbai, and Delhi, India delivers world-class neurosurgical outcomes at 50–65% lower cost than equivalent care in the UAE or Western countries. In the UAE (Dubai and Abu Dhabi), the same treatment range costs between $15,000 and $55,000 USD at JCI-accredited and DHA/DOH-licensed institutions such as Cleveland Clinic Abu Dhabi, Burjeel Medical City, and Mediclinic City Hospital Dubai. These estimates cover the primary surgical episode and standard inpatient stay. Multi-cycle adjuvant chemotherapy (e.g., 6 cycles of temozolomide at $500–$2,500 USD per cycle in India), proton beam therapy (approximately $20,000–$40,000 USD per course), and extended inpatient rehabilitation are priced separately and are always itemised transparently by GAF Healthcare in the pre-departure cost estimate.

The minimum safe in-country stay before international air travel is cleared depends on the type of brain cancer treatment received. For patients who undergo a craniotomy (open brain surgery), the treating neurosurgeon will typically clear the patient to fly internationally no earlier than 4–6 weeks after surgery. This timeframe allows adequate wound healing, resolution of perioperative cerebral edema, normalization of intracranial pressure, stable neurological recovery, and a post-operative MRI to confirm the absence of surgical complications. Patients with a high risk of deep vein thrombosis (DVT) or pulmonary embolism — which are elevated in neuro-oncology patients — require anticoagulation management and DVT exclusion before long-haul flights. For patients treated with stereotactic radiosurgery (Gamma Knife or CyberKnife) for brain metastases or small tumors, fitness to fly is typically assessed at 1–2 weeks after the procedure, pending neurological stability and the treating radiation oncologist's review. For patients who begin a 6-week (30-fraction) course of adjuvant radiotherapy in-country, the total stay will extend to approximately 8–10 weeks. GAF Healthcare ensures that the formal fitness-to-fly certificate is issued by the treating neurosurgeon or oncologist and that in-flight medical documentation, medication packs, and wheelchair assistance (where needed) are arranged prior to departure.

Success rates in brain cancer treatment vary substantially by tumor type, WHO grade, molecular profile, surgical resectability, and patient performance status, and must be understood in that context. For surgically resectable low-grade gliomas (WHO Grade II, IDH-mutant) and benign meningiomas (Grade I), gross total resection achieves 5-year progression-free survival rates of 80–92%, and 10-year overall survival exceeding 70–80%. Anaplastic gliomas (Grade III, IDH-mutant with 1p/19q codeletion — oligodendroglioma) treated with surgery plus PCV chemotherapy and radiotherapy show median overall survival exceeding 14 years in recent randomized trials. For glioblastoma multiforme (GBM, WHO Grade IV) — the most common and aggressive primary brain tumor in adults — the Stupp protocol (concurrent temozolomide + radiotherapy followed by adjuvant temozolomide) yields a median overall survival of 14–16 months, with approximately 5–10% of patients surviving 5 years; MGMT promoter-methylated GBM patients fare significantly better (median OS ~21–23 months). The addition of Tumor Treating Fields (Optune) to temozolomide extended median OS to 20.9 months versus 16 months in the landmark EF-14 Phase III trial. For brain metastases treated with stereotactic radiosurgery (SRS), local tumor control rates at 1 year exceed 85–90%. Pituitary adenomas treated endoscopically achieve remission in 70–90% of functioning tumors. GAF Healthcare's partner hospitals report gross total resection rates of 70–85% for operable tumors, consistent with international benchmarks at JCI-accredited high-volume neuro-oncology centers.